NASDAQ:ABUS - Arbutus Biopharma News Headlines

Sign in or create an account to add this stock to your watchlist.
$3.79 +0.04 (+1.07 %)
(As of 02/22/2019 04:00 PM ET)
Previous Close$3.79
Today's Range$3.75 - $3.90
52-Week Range$3.20 - $12.60
Volume133,899 shs
Average Volume150,492 shs
Market Capitalization$210.27 million
P/E Ratio-2.12
Dividend YieldN/A
Beta2

Headlines

Arbutus Biopharma (NASDAQ ABUS) News Headlines

Source:
DateHeadline
Arbutus Biopharma Corp (ABUS) Expected to Post Quarterly Sales of $770,000.00Arbutus Biopharma Corp (ABUS) Expected to Post Quarterly Sales of $770,000.00
www.americanbankingnews.com - February 11 at 2:20 AM
Arbutus Biopharma Corp (ABUS) Expected to Post Earnings of -$0.39 Per ShareArbutus Biopharma Corp (ABUS) Expected to Post Earnings of -$0.39 Per Share
www.americanbankingnews.com - February 9 at 7:12 PM
Notable Friday Option Activity: X, ABUS, CBIONotable Friday Option Activity: X, ABUS, CBIO
www.nasdaq.com - February 8 at 7:06 PM
Arbutus Biopharma Corp (ABUS) Given Consensus Rating of "Hold" by AnalystsArbutus Biopharma Corp (ABUS) Given Consensus Rating of "Hold" by Analysts
www.americanbankingnews.com - January 31 at 9:12 AM
Arbutus Biopharma Corp.Arbutus Biopharma Corp.
www.barrons.com - January 25 at 6:13 PM
Can We See Significant Insider Ownership On The Arbutus Biopharma Corporation (NASDAQ:ABUS) Share Register?Can We See Significant Insider Ownership On The Arbutus Biopharma Corporation (NASDAQ:ABUS) Share Register?
finance.yahoo.com - January 22 at 6:25 PM
Do Hedge Funds Love Arbutus Biopharma Corp (ABUS)?Do Hedge Funds Love Arbutus Biopharma Corp (ABUS)?
finance.yahoo.com - December 23 at 8:14 AM
New Research Coverage Highlights Nokia, SecureWorks, National Western Life Group, Brookfield AssetNew Research Coverage Highlights Nokia, SecureWorks, National Western Life Group, Brookfield Asset
www.nasdaq.com - December 11 at 8:44 AM
Why Arbutus Biopharma Corporation’s (NASDAQ:ABUS) CEO Pay Matters To YouWhy Arbutus Biopharma Corporation’s (NASDAQ:ABUS) CEO Pay Matters To You
finance.yahoo.com - December 5 at 5:18 PM
Arbutus Appoints Dr. Frank Torti as Chairman of its Board of DirectorsArbutus Appoints Dr. Frank Torti as Chairman of its Board of Directors
finance.yahoo.com - November 26 at 5:19 PM
Top Ranked Momentum Stocks to Buy for November 23rdTop Ranked Momentum Stocks to Buy for November 23rd
www.zacks.com - November 23 at 8:25 AM
Options Traders Expect Huge Moves in Arbutus (ABUS) StockOptions Traders Expect Huge Moves in Arbutus (ABUS) Stock
finance.yahoo.com - November 21 at 5:12 PM
Arbutus Biopharma Corps (ABUS) CEO Mark Murray on Q3 2018 Results - Earnings Call TranscriptArbutus Biopharma Corp's (ABUS) CEO Mark Murray on Q3 2018 Results - Earnings Call Transcript
seekingalpha.com - November 8 at 8:20 AM
Arbutus Biopharma misses by $0.08Arbutus Biopharma misses by $0.08
seekingalpha.com - November 7 at 5:49 PM
Arbutus Reports 2018 Third Quarter Financial Results and Provides Corporate UpdateArbutus Reports 2018 Third Quarter Financial Results and Provides Corporate Update
finance.yahoo.com - November 7 at 5:49 PM
Arbutus to Report Third Quarter 2018 Financial ResultsArbutus to Report Third Quarter 2018 Financial Results
finance.yahoo.com - October 31 at 5:30 PM
Arbutus Biopharma (ABUS) Q3 Earnings Preview: What to ExpectArbutus Biopharma (ABUS) Q3 Earnings Preview: What to Expect
www.zacks.com - October 26 at 8:22 AM
Arbutus Names New Members to its Board of DirectorsArbutus Names New Members to its Board of Directors
finance.yahoo.com - October 22 at 5:22 PM
What Kind Of Risk Should You Expect For Arbutus Biopharma Corporation (NASDAQ:ABUS)?What Kind Of Risk Should You Expect For Arbutus Biopharma Corporation (NASDAQ:ABUS)?
finance.yahoo.com - October 17 at 4:59 PM
Arbutus Bio down 24% on delay of early-stage study of HBV candidate AB-452Arbutus Bio down 24% on delay of early-stage study of HBV candidate AB-452
seekingalpha.com - October 9 at 4:57 PM
Why Arbutus Biopharma Stock Plunged 24.4% TodayWhy Arbutus Biopharma Stock Plunged 24.4% Today
finance.yahoo.com - October 9 at 4:57 PM
Here's Why Arbutus Biopharma Corp. Is Tanking TodayHere's Why Arbutus Biopharma Corp. Is Tanking Today
finance.yahoo.com - October 9 at 4:57 PM
Heres Why Arbutus Biopharma Corp. Is Tanking TodayHere's Why Arbutus Biopharma Corp. Is Tanking Today
www.fool.com - October 9 at 3:28 PM
Arbutus to Present at Chardan’s Genetic Medicines ConferenceArbutus to Present at Chardan’s Genetic Medicines Conference
finance.yahoo.com - October 2 at 4:52 PM
Are Options Traders Betting on a Big Move in Arbutus (ABUS) Stock?Are Options Traders Betting on a Big Move in Arbutus (ABUS) Stock?
www.zacks.com - September 24 at 8:16 AM
Arbutus to Participate at the 2018 B. Riley FBR Healthcare ConferenceArbutus to Participate at the 2018 B. Riley FBR Healthcare Conference
finance.yahoo.com - August 28 at 4:57 PM
More Volatility Ahead For Arbutus BiopharmaMore Volatility Ahead For Arbutus Biopharma
seekingalpha.com - August 17 at 5:36 PM
Alnylam Receives First Ever FDA Approval For RNAi Therapeutic Treating Rare Disease Making HistoryAlnylam Receives First Ever FDA Approval For RNAi Therapeutic Treating Rare Disease Making History
seekingalpha.com - August 13 at 8:13 AM
Arbutus to Present at the 2018 Wedbush PacGrow Healthcare ConferenceArbutus to Present at the 2018 Wedbush PacGrow Healthcare Conference
feeds.benzinga.com - August 9 at 8:40 AM
Arbutus down 16% after Q2 reportArbutus down 16% after Q2 report
seekingalpha.com - August 3 at 4:34 PM
Arbutus Biopharma Corp (ABUS) CEO Mark Murray on Q2 2018 Results - Earnings Call TranscriptArbutus Biopharma Corp (ABUS) CEO Mark Murray on Q2 2018 Results - Earnings Call Transcript
seekingalpha.com - August 3 at 8:23 AM
Arbutus Reports 2018 Second Quarter Financial Results and Provides Corporate UpdateArbutus Reports 2018 Second Quarter Financial Results and Provides Corporate Update
finance.yahoo.com - August 2 at 5:32 PM
ContraVir Stock Rose on Clinical Trial Progress ReportContraVir Stock Rose on Clinical Trial Progress Report
finance.yahoo.com - July 24 at 8:38 AM
Arbutus Biopharma (ABUS) Shares March Higher, Can It Continue?Arbutus Biopharma (ABUS) Shares March Higher, Can It Continue?
finance.yahoo.com - July 20 at 5:14 PM
Arbutus to Report Second Quarter 2018 Financial ResultsArbutus to Report Second Quarter 2018 Financial Results
globenewswire.com - July 19 at 4:45 PM
Opinion: Harry Boxers three drug stocks to watchOpinion: Harry Boxer's three drug stocks to watch
www.marketwatch.com - July 19 at 4:45 PM
Arbutus: An Extremely Promising RNAi Innovator Hitting Its Growth InflectionArbutus: An Extremely Promising RNAi Innovator Hitting Its Growth Inflection
seekingalpha.com - July 19 at 8:15 AM
Arbutus Biopharma: Long-Term Growth Prospect Flying Too Close To The SunArbutus Biopharma: Long-Term Growth Prospect Flying Too Close To The Sun
seekingalpha.com - July 18 at 4:52 PM
Arbutus Presents Corporate Update on Key MilestonesArbutus Presents Corporate Update on Key Milestones
finance.yahoo.com - July 10 at 8:16 AM
B.Riley/FBR Downgrades Arbutus Biopharma (ABUS) to NeutralB.Riley/FBR Downgrades Arbutus Biopharma (ABUS) to Neutral
www.streetinsider.com - July 6 at 8:15 AM
Form 4 Arbutus Biopharma Corp For: Jun 19 Filed by: HENRIQUES RICHARD C JRForm 4 Arbutus Biopharma Corp For: Jun 19 Filed by: HENRIQUES RICHARD C JR
www.streetinsider.com - June 27 at 8:57 AM
Arbutus Biopharma: The Next Big Breakout Biotech?Arbutus Biopharma: The Next Big Breakout Biotech?
seekingalpha.com - June 22 at 5:42 PM
Arbutus Biopharma to Present at First Annual Roivant Pipeline DayArbutus Biopharma to Present at First Annual Roivant Pipeline Day
finance.yahoo.com - June 18 at 8:50 AM
Arbutus appoints David C. Hastings as new Chief Financial OfficerArbutus appoints David C. Hastings as new Chief Financial Officer
seekingalpha.com - June 8 at 8:17 AM
Arbutus Biopharma (ABUS) Announces Appointment of David C. Hastings as New Chief Financial OfficerArbutus Biopharma (ABUS) Announces Appointment of David C. Hastings as New Chief Financial Officer
www.streetinsider.com - June 8 at 8:17 AM
Arbutus Biopharmas (ABUS) CEO Mark Murray on Q1 2018 Results - Earnings Call TranscriptArbutus Biopharma's (ABUS) CEO Mark Murray on Q1 2018 Results - Earnings Call Transcript
seekingalpha.com - May 6 at 7:42 PM
Arbutus Biopharma (ABUS) Reports Q1 Loss of $0.36/ShareArbutus Biopharma (ABUS) Reports Q1 Loss of $0.36/Share
www.streetinsider.com - May 4 at 5:34 PM
BRIEF-Arbutus Reports Q1 Loss Per Share $0.36BRIEF-Arbutus Reports Q1 Loss Per Share $0.36
www.reuters.com - May 4 at 8:18 AM
Arbutus: 1Q Earnings SnapshotArbutus: 1Q Earnings Snapshot
finance.yahoo.com - May 4 at 8:18 AM
Arbutus Biopharma beats by $0.03, beats on revenueArbutus Biopharma beats by $0.03, beats on revenue
seekingalpha.com - May 3 at 5:25 PM
This page was last updated on 2/23/2019 by MarketBeat.com Staff

Featured Article: Buyback

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.

Yahoo Gemini Pixel